Geron Corp Stock Price, News & Analysis

Geron Corporation (NASDAQ: GERN), a biopharmaceutical company focused on hematologic malignancies, announced that CEO John A. Scarlett will present at the H.C. Wainwright Global Investment Conference. The on-demand presentation starts on May 24, 2022, at 7 a.m. ET. A webcast will be accessible in the Investor Relations section of Geron's website, with an archive available for 30 days after the event. Geron is advancing its lead candidate, imetelstat, through two Phase 3 trials: IMerge for lower risk myelodysplastic syndromes and IMpactMF for refractory myelofibrosis.

Geron Corporation (Nasdaq: GERN) reported its Q1 2022 financial results, highlighting a net loss of $30.1 million, unchanged EPS at $0.09, and revenues of $123,000. The company has $178 million in cash and marketable securities and completed a public offering in April, raising approximately $70 million. The company anticipates sufficient resources to support operations through the end of 2023. Key milestones include the upcoming Phase 3 IMerge trial results and the initiation of the IMproveMF study, aiming to enhance treatment options for hematologic malignancies.

Geron Corporation (NASDAQ: GERN) will release its first quarter 2022 financial results on May 9, 2022, after market close. A conference call is scheduled for 4:30 p.m. ET the same day to discuss the results and recent developments. Geron is focused on developing imetelstat, a first-in-class telomerase inhibitor, currently in two Phase 3 trials: IMerge for lower risk myelodysplastic syndromes and IMpactMF for refractory myelofibrosis. The press release and webcast details are accessible on their website.

Geron Corporation (NASDAQ: GERN) announced the grant of non-statutory stock options for 505,800 shares of common stock to newly hired employees as an inducement for employment. The options, granted on April 20, 2022, have an exercise price of $1.47, matching the stock's closing price on that date. They have a 10-year term and will vest over four years, beginning with a 12.5% vesting at six months. Geron is focused on developing imetelstat, a telomerase inhibitor, currently in two Phase 3 clinical trials for hematologic malignancies.

Geron Corporation (NASDAQ: GERN) announced that CEO John A. Scarlett will present a company overview at the 21st Annual Needham Virtual Healthcare Conference on April 13, 2022, at 3:45 p.m. ET. The presentation can be accessed via a live webcast on Geron's Investor Relations website, with an archived replay available for 30 days afterward.

Geron is focused on the development of imetelstat, a first-in-class telomerase inhibitor, currently in two Phase 3 trials: IMerge for lower risk myelodysplastic syndromes and IMpactMF for refractory myelofibrosis.

Geron Corporation (NASDAQ: GERN) has successfully closed an underwritten public offering, raising approximately $70 million by selling 53,333,334 shares of common stock and 18,095,238 pre-funded warrants. Each share was priced at $1.05 with accompanying warrants. The net proceeds will be used to support regulatory filings for imetelstat in myelodysplastic syndromes and to fund ongoing clinical trials for myelofibrosis and other indications. This financing positions Geron for further advancements in its pipeline.

Geron Corporation (Nasdaq: GERN) announced a public offering of 53,333,334 shares of common stock and pre-funded warrants to purchase an additional 18,095,238 shares, along with warrants for 35,714,286 shares. The offering price is set at $1.05 per share and $1.049 for pre-funded warrants, expected to generate gross proceeds of approximately $75 million. Funds will support regulatory filings for imetelstat in myelodysplastic syndromes and the completion of clinical trials in refractory myelofibrosis and additional indications. The offering is subject to customary closing conditions.

Geron Corporation (NASDAQ: GERN) plans to conduct an underwritten public offering of its common stock and pre-funded warrants. The offering is subject to market conditions and no guarantee of completion exists. Stifel and Baird are joint book-running managers, with Needham & Company acting as the lead manager. A shelf registration statement has been filed with the SEC, and a preliminary prospectus will be available. Geron focuses on developing imetelstat, a telomerase inhibitor, for hematologic malignancies, currently in two Phase 3 trials.

Geron Corporation (Nasdaq: GERN) announced the grant of non-statutory stock options for 320,000 shares of common stock to new employees as inducements for their commencement of employment. The options, set at an exercise price of $1.03 per share, have a 10-year term and will vest over four years. This grant adheres to Nasdaq Listing Rule 5635(c)(4) and is part of Geron's 2018 Inducement Award Plan. The company is currently engaged in two Phase 3 clinical trials for its telomerase inhibitor, imetelstat, targeting hematologic malignancies.